CD274 and neoplasm: Data from the final OS analysis at a median follow-up of 18.8 months were presented at the 2020 ESMO Congress confirming previous results [11]: In the ITT population, a trend towards improved OS was observed, with a prolongation of OS from 18.7 to 21.0 months (HR 0.87; 95% CI 0.75–1.02; p = 0.077); this difference was again driven by the PD-L1-positive subset (OS 17.9 vs. 25.4 months; HR 0.67; 95% CI 0.53–0.86) while no benefit was observed in PD-L1 negative tumours.